Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.
Verywell Health on MSN
IV vs. subcutaneous cancer therapies: What’s the difference?
Medically reviewed by Marla Anderson, MD Key Takeaways IV therapy delivers cancer medicine directly into a vein and often ...
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple ...
A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...
This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
Please provide your email address to receive an email when new articles are posted on . Subcutaneous delivery reduced administration time from several hours to less than 5 minutes. Although unexpected ...
Please provide your email address to receive an email when new articles are posted on . The subcutaneous pembrolizumab combination was approved for adults and ...
A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...
Independently developed by Junshi Biosciences, JS001sc injection is a subcutaneous injection based on the marketed product toripalimab injection (code: JS001) that is expected to enhance convenience ...
ZURICH, Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous ...
Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the development and commercialization of subcutaneous (SC) formulations of ...
Many professionals report awareness, but few actively prescribe the self-administered injectable contraceptive DMPA. HealthDay News — About one-third of health care professionals who are aware of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results